- Report
- August 2025
- 189 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 150 Pages
Global
From €2505EUR$2,850USD£2,167GBP
€3384EUR$3,850USD£2,927GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2637EUR$3,000USD£2,281GBP
- Report
- January 2025
- 250 Pages
Global
From €4394EUR$4,999USD£3,801GBP
- Report
- June 2025
- 200 Pages
Global
From €2451EUR$2,789USD£2,120GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2451EUR$2,789USD£2,120GBP
- Report
- May 2024
- 138 Pages
Global
From €5712EUR$6,499USD£4,941GBP
- Report
- December 2023
- 100 Pages
Africa
From €879EUR$1,000USD£760GBP
€1758EUR$2,000USD£1,521GBP
- Report
- December 2023
- 180 Pages
Global
From €1099EUR$1,250USD£950GBP
€2197EUR$2,500USD£1,901GBP
- Report
- December 2023
- 80 Pages
United States
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
United Kingdom
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
South Korea
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
Saudi Arabia
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
Russia
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
India
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
Germany
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
France
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- December 2023
- 80 Pages
China
From €659EUR$750USD£570GBP
€1318EUR$1,500USD£1,140GBP
- Report
- August 2024
- 89 Pages
Global
From €3500EUR$4,266USD£3,133GBP

The Castration Resistant Prostate Cancer Drug market is a subset of the larger Prostate Cancer Drug market. It is composed of drugs that are used to treat prostate cancer that has become resistant to hormone therapy, also known as androgen deprivation therapy. These drugs are used to reduce the levels of testosterone and other hormones that can fuel the growth of prostate cancer cells. Commonly used drugs in this market include abiraterone acetate, enzalutamide, and apalutamide.
The Castration Resistant Prostate Cancer Drug market is highly competitive, with many companies offering their own versions of these drugs. Some of the major players in this market include Astellas Pharma, Janssen Pharmaceuticals, Pfizer, Sanofi, and Bayer. Show Less Read more